MedPath

Prednisone

Generic Name
Prednisone
Brand Names
Deltasone, Rayos, Winpred
Drug Type
Small Molecule
Chemical Formula
C21H26O5
CAS Number
53-03-2
Unique Ingredient Identifier
VB0R961HZT

Overview

A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver. Prednisone was granted FDA approval on 21 February 1955.

Indication

Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions

  • Acne Vulgaris
  • Acute Exacerbation of Chronic Obstructive Pulmonary Disease
  • Acute Gouty Arthritis
  • Acute Leukemia
  • Aggressive Lymphoma
  • Allergic Bronchopulmonary Aspergillosis
  • Allergic Conjunctivitis (AC)
  • Allergic Rhinitis (AR)
  • Allergic corneal marginal ulcers
  • Alveolitis, Extrinsic Allergic
  • Ankylosing Spondylitis (AS)
  • Aspiration Pneumonitis
  • Asthma
  • Atopic Dermatitis
  • Autoimmune Hepatitis
  • Bell's Palsy
  • Berylliosis
  • Bullous dermatitis herpetiformis
  • Chorioretinitis
  • Congenital Adrenal Hyperplasia (CAH)
  • Congenital Hypoplastic Anemia
  • Contact Dermatitis
  • Disseminated tuberculosis
  • Drug hypersensitivity reaction
  • Edema of the cerebrum
  • Epicondylitis
  • Erythroblastopenia
  • Giant Cell Arteritis (GCA)
  • Hypercalcemia of Malignancy
  • Idiopathic Pulmonary Fibrosis (IPF)
  • Immune Thrombocytopenia (ITP)
  • Iridocyclitis
  • Iritis
  • Keratitis
  • Leukemias
  • Loeffler's syndrome
  • Lymphoma
  • Meningitis caused by Mycobacterium Tuberculosis
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Mycosis Fungoides (MF)
  • Ocular Inflammation
  • Ophthalmia, Sympathetic
  • Optic Neuritis
  • Pain caused by Herpes zoster
  • Pemphigus
  • Pericarditis
  • Pneumocystis Jirovecii Pneumonia
  • Polymyalgia Rheumatica (PMR)
  • Polymyositis
  • Posterior Uveitis
  • Primary adrenocortical insufficiency
  • Psoriatic Arthritis
  • Pure Red Cell Aplasia
  • Regional Enteritis
  • Relapsing Polychondritis
  • Rheumatoid Arthritis
  • Rheumatoid Arthritis, Juvenile
  • Secondary adrenocortical insufficiency
  • Secondary thrombocytopenia
  • Serum Sickness
  • Severe Seborrheic Dermatitis
  • Sjogren's Syndrome (SS)
  • Solid Organ Transplant Rejection
  • Stevens-Johnson Syndrome
  • Systemic Lupus Erythematosus
  • Takayasu Arteritis
  • Thyroid Eye Disease
  • Thyroiditis
  • Thyrotoxicosis
  • Trichinosis
  • Ulcerative Colitis
  • Uveitis
  • Vasculitis
  • Acquired immune hemolytic anemia
  • Acute Bursitis
  • Acute Crohn's Disease (CD)
  • Acute Multiple sclerosis exacerbation
  • Acute rheumatic carditis
  • Anterior eye segment inflammation
  • Exfoliative erythroderma
  • Fulminating Tuberculosis
  • Idiopathic Bronchiolitis obliterans with organizing pneumonia
  • Idiopathic eosinophilic pneumonias
  • Non-suppurative Thyroiditis
  • Severe Psoriasis
  • Subacute Bursitis
  • Symptomatic Sarcoidosis
  • Synovitis of osteoarthritis
  • Systemic Dermatomyositis
  • Varicella-zoster virus acute retinal necrosis

Research Report

Published: Jul 16, 2025

Comprehensive Monograph on Prednisone (DB00635)

[Executive Summary]

Prednisone is a potent, synthetically produced glucocorticoid that has served as a cornerstone of anti-inflammatory and immunosuppressive therapy for over half a century, following its initial FDA approval on February 21, 1955.[1] It functions as a biologically inert prodrug, requiring hepatic conversion to its active metabolite, prednisolone, to exert its therapeutic effects.[1] Its mechanism of action is profound and ubiquitous, involving the binding to glucocorticoid receptors present in nearly every cell type in the body.[3] This interaction leads to complex downstream effects on gene expression, primarily the suppression of pro-inflammatory pathways and the enhancement of anti-inflammatory processes. This broad mechanism underpins Prednisone's remarkable efficacy across an extensive spectrum of clinical conditions, including rheumatologic, respiratory, allergic, hematologic, neoplastic, and autoimmune diseases, as well as in the prevention of organ transplant rejection.[1]

Continue reading the full research report

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/08/15
Not Applicable
Recruiting
2025/07/31
Not Applicable
Not yet recruiting
2025/07/18
Not Applicable
Not yet recruiting
2025/07/16
Not Applicable
Not yet recruiting
2025/07/11
Not Applicable
Not yet recruiting
Samer Gawrieh
2025/06/24
Phase 2
Not yet recruiting
2025/06/05
Phase 2
Recruiting
2025/05/21
Phase 3
Not yet recruiting
2025/05/18
Phase 1
Recruiting
2025/05/02
Phase 2
Recruiting
Jennifer Amengual

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
A-S Medication Solutions
50090-0439
ORAL
5 mg in 1 1
8/19/2022
ANI Pharmaceuticals, Inc.
70954-061
ORAL
50 mg in 1 1
2/16/2024
QPharma Inc
42708-045
ORAL
10 mg in 1 1
12/8/2023
NCS HealthCare of KY, LLC dba Vangard Labs
0615-8391
ORAL
10 mg in 1 1
8/2/2022
Northwind Pharmaceuticals
51655-763
ORAL
2.5 mg in 1 1
1/1/2023
A-S Medication Solutions
50090-1455
ORAL
2.5 mg in 1 1
1/5/2023
Diect_Rx
61919-326
ORAL
20 mg in 1 1
8/7/2019
A-S Medication Solutions
50090-4784
ORAL
20 mg in 1 1
4/30/2019
RedPharm Drug, Inc.
67296-1767
ORAL
10 mg in 1 1
1/21/2022
RPK Pharmaceuticals, Inc.
53002-3090
ORAL
10 mg in 1 1
12/7/2017

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
APO-PREDNISONE TABLET 5 mg
SIN04379P
TABLET
5 mg
5/3/1990

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
PREDNISONE 50 TAB 50MG
PRO DOC LIMITEE
00607517
Tablet - Oral
50 MG
12/31/1994
NU-PREDNISONE
nu-pharm inc
02239539
Tablet - Oral
1 MG
N/A
TEVA-PREDNISONE
teva canada limited
00232378
Tablet - Oral
50 MG
12/31/1972
APO PREDNISONE TAB 1MG USP
00598194
Tablet - Oral
1 MG
12/31/1984
DELTASONE 5MG
pharmacia & upjohn inc
00210188
Tablet - Oral
5 MG / TAB
12/31/1972
NU-PREDNISONE
nu-pharm inc
02239541
Tablet - Oral
50 MG
N/A
METRETON TAB
schering-plough canada inc
00177091
Tablet - Oral
2.5 MG
12/31/1956
JAA PREDNISONE TAB 5MG USP
jaapharm canada inc.
00868442
Tablet - Oral
5 MG
12/31/1993
WINPRED TAB 5MG
valeant canada lp / valeant canada s.e.c.
00271381
Tablet - Oral
5 MG
12/31/1985
JAA PREDNISONE TAB 1MG USP
jaapharm canada inc.
00868426
Tablet - Oral
1.0 MG
5/15/1993

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
PREDNISONA TARBIS 30 mg COMPRIMIDOS EFG
Tarbis Farma S.L.
75677
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración
Commercialized
PREDNISONA TARBIS 10 mg COMPRIMIDOS
Tarbis Farma S.L.
75641
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración
Commercialized
PREDNISONA CINFA 5 mg COMPRIMIDOS EFG
Laboratorios Cinfa S.A.
75647
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración
Commercialized
PREDNISONA CINFA 30 mg COMPRIMIDOS EFG
Laboratorios Cinfa S.A.
75676
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración
Commercialized
PREDNISONA CINFA 2,5 mg COMPRIMIDOS EFG
Laboratorios Cinfa S.A.
75644
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración
Commercialized
DACORTIN 2,5 mg COMPRIMIDOS
Laboratorios Ern S.A.
47863
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración
Commercialized
PREDNISONA KERN PHARMA 30 mg COMPRIMIDOS EFG
70108
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración
Commercialized
PREDNISONA ALONGA 50 mg COMPRIMIDOS
58336
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración
Not Commercialized
PREDNISONA TARBIS 2,5 mg COMPRIMIDOS EFG
Tarbis Farma S.L.
75634
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración
Commercialized
PREDNISONA KERN PHARMA 5 mg COMPRIMIDOS EFG
70106
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración
Commercialized

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.